ciprofloxacin has been researched along with Chemical and Drug Induced Liver Injury in 29 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
Excerpt | Relevance | Reference |
---|---|---|
" Neutropenia and thrombocytopenia associated with cefoxitin developed in 33 (51%) and 4 (6%) patients, respectively." | 3.75 | Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. ( Jeon, K; Kim, BJ; Kim, CK; Koh, WJ; Kook, YH; Kwon, OJ; Lee, NY; Lee, SH; Park, YK, 2009) |
"Twenty-five patients who had extensive pulmonary tuberculosis and hepatitis induced by antituberculosis drugs were treated with ciprofloxacin together with other relatively non-hepatotoxic drugs, either during the interim phase awaiting recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others." | 2.68 | Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction. ( Chan, CY; Chau, CH; Cheng, AF; Cheung, SW; Lee, J; Wong, CF; Wong, PC; Yew, WW, 1995) |
"Ciprofloxacin is a common, broad spectrum antibacterial agent; however, evidence is accumulating that ciprofloxacin may cause liver damage." | 1.43 | Quercetin protection against ciprofloxacin induced liver damage in rats. ( Cetin, A; Dogan, Z; Elbe, H; Taslidere, E; Turkoz, Y; Vardi, N, 2016) |
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
"Ciprofloxacin is a fluoroquinolone antibiotic that has a relatively low rate of occurence of adverse side effects." | 1.37 | Unexpected severe hepatotoxicity of ciprofloxacine: two case reports. ( Alan, C; Ersay, AR; Ertung, Y; Koçoğlu, H; Kurt, HA, 2011) |
"Surveillance of ciprofloxacin usage in a pediatric population failed to demonstrate serious or unusually high rates of any adverse events, including joint toxicity." | 1.30 | Ciprofloxacin safety in a pediatric population. ( Jick, S, 1997) |
"It is suggested that ciprofloxacin can cause severe hepatic injury and that healthcare providers should be aware of this possible adverse drug reaction." | 1.29 | Suspected ciprofloxacin-induced hepatotoxicity. ( Côté, J; Davies, C; Villeneuve, JP, 1995) |
"Ciprofloxacin was started on postoperative day 13 for treatment of a urinary tract infection." | 1.28 | Fulminant hepatic failure possibly related to ciprofloxacin. ( Grassmick, BK; Lehr, VT; Sundareson, AS, 1992) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (20.69) | 18.2507 |
2000's | 8 (27.59) | 29.6817 |
2010's | 14 (48.28) | 24.3611 |
2020's | 1 (3.45) | 2.80 |
Authors | Studies |
---|---|
Fourches, D | 1 |
Barnes, JC | 1 |
Day, NC | 1 |
Bradley, P | 1 |
Reed, JZ | 1 |
Tropsha, A | 1 |
Morgan, RE | 2 |
Trauner, M | 1 |
van Staden, CJ | 2 |
Lee, PH | 1 |
Ramachandran, B | 1 |
Eschenberg, M | 1 |
Afshari, CA | 2 |
Qualls, CW | 1 |
Lightfoot-Dunn, R | 1 |
Hamadeh, HK | 2 |
Chen, M | 2 |
Vijay, V | 1 |
Shi, Q | 2 |
Liu, Z | 2 |
Fang, H | 2 |
Tong, W | 3 |
Ding, D | 1 |
Kelly, R | 1 |
Sakatis, MZ | 1 |
Reese, MJ | 1 |
Harrell, AW | 1 |
Taylor, MA | 1 |
Baines, IA | 1 |
Chen, L | 1 |
Bloomer, JC | 1 |
Yang, EY | 1 |
Ellens, HM | 1 |
Ambroso, JL | 1 |
Lovatt, CA | 1 |
Ayrton, AD | 1 |
Clarke, SE | 1 |
Warner, DJ | 1 |
Chen, H | 1 |
Cantin, LD | 1 |
Kenna, JG | 1 |
Stahl, S | 1 |
Walker, CL | 1 |
Noeske, T | 1 |
Chen, Y | 1 |
Kalyanaraman, N | 1 |
Kalanzi, J | 1 |
Dunn, RT | 1 |
Suzuki, A | 1 |
Thakkar, S | 1 |
Yu, K | 1 |
Hu, C | 1 |
Gu, S | 1 |
Rajendiran, G | 1 |
Forest, K | 1 |
Tran, TC | 1 |
Denny, JC | 1 |
Larson, EA | 1 |
Wilke, RA | 1 |
Amorha, KC | 1 |
Ugwuowo, OB | 1 |
Ayogu, EE | 1 |
Nduka, SO | 1 |
Okonta, MJ | 1 |
Radovanovic, M | 1 |
Dushenkovska, T | 1 |
Cvorovic, I | 1 |
Radovanovic, N | 1 |
Ramasamy, V | 1 |
Milosavljevic, K | 1 |
Surla, J | 1 |
Jecmenica, M | 1 |
Radulovic, M | 1 |
Milovanovic, T | 1 |
Dumic, I | 1 |
Alshammari, TM | 1 |
Larrat, EP | 1 |
Morrill, HJ | 1 |
Caffrey, AR | 1 |
Quilliam, BJ | 1 |
LaPlante, KL | 1 |
Taslidere, E | 1 |
Dogan, Z | 1 |
Elbe, H | 1 |
Vardi, N | 1 |
Cetin, A | 1 |
Turkoz, Y | 1 |
Moreno, L | 1 |
Sánchez-Delgado, J | 1 |
Vergara, M | 1 |
Casas, M | 1 |
Miquel, M | 1 |
Dalmau, B | 1 |
Bhagirath, KM | 1 |
Jeon, K | 1 |
Kwon, OJ | 1 |
Lee, NY | 1 |
Kim, BJ | 1 |
Kook, YH | 1 |
Lee, SH | 1 |
Park, YK | 1 |
Kim, CK | 1 |
Koh, WJ | 1 |
Alan, C | 1 |
Koçoğlu, H | 1 |
Ersay, AR | 1 |
Ertung, Y | 1 |
Kurt, HA | 1 |
Hauben, M | 1 |
Bataille, L | 1 |
Rahier, J | 1 |
Geubel, A | 1 |
Zaidi, SA | 1 |
Marra, F | 1 |
Cox, VC | 1 |
FitzGerald, JM | 1 |
Moadebi, S | 1 |
Elwood, RK | 1 |
Yew, WW | 1 |
Chau, CH | 1 |
Wong, PC | 1 |
Lee, J | 1 |
Wong, CF | 1 |
Cheung, SW | 1 |
Chan, CY | 1 |
Cheng, AF | 1 |
Villeneuve, JP | 1 |
Davies, C | 1 |
Côté, J | 1 |
Hautekeete, ML | 1 |
Kockx, MM | 1 |
Naegels, S | 1 |
Holvoet, JK | 1 |
Hubens, H | 1 |
Kloppel, G | 1 |
Jick, S | 1 |
Contreras, MA | 1 |
Luna, R | 1 |
Mulero, J | 1 |
Andreu, JL | 1 |
Clark, DW | 1 |
Layton, D | 1 |
Wilton, LV | 1 |
Pearce, GL | 1 |
Shakir, SA | 1 |
Grassmick, BK | 1 |
Lehr, VT | 1 |
Sundareson, AS | 1 |
Chiu, J | 1 |
Nussbaum, J | 1 |
Bozzette, S | 1 |
Tilles, JG | 1 |
Young, LS | 1 |
Leedom, J | 1 |
Heseltine, PN | 1 |
McCutchan, JA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Efficacy and Safety of 36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-Induced Liver Injury[NCT03266146] | Phase 1/Phase 2 | 90 participants (Actual) | Interventional | 2017-09-02 | Completed | ||
A Randomized Controlled Clinical Trial on the Efficacy and Safety of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-induced Liver Injury[NCT02651350] | Phase 1/Phase 2 | 80 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 reviews available for ciprofloxacin and Chemical and Drug Induced Liver Injury
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Idiosyncratic Drug-Induced Liver Injury Due to Ciprofloxacin: A Report of Two Cases and Review of the Literature.
Topics: Adult; Aged, 80 and over; Anti-Bacterial Agents; Chemical and Drug Induced Liver Injury; Ciprofloxac | 2018 |
1 trial available for ciprofloxacin and Chemical and Drug Induced Liver Injury
Article | Year |
---|---|
Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cipro | 1995 |
26 other studies available for ciprofloxacin and Chemical and Drug Induced Liver Injury
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Drug-Induced Liver Injury with Commonly Used Antibiotics in the All of Us Research Program.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Cep | 2023 |
Evaluation of the hepatic effect of concomitant administration of ciprofloxacin and some antimalarial drugs in Plasmodium berghei infected mice: An in vivo study.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Chemical and Drug Induced Liver Injury; Ciprofloxacin | 2018 |
Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.
Topics: Adult; Aged; Alcoholism; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Chemical and Dr | 2014 |
Quercetin protection against ciprofloxacin induced liver damage in rats.
Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Ciprofloxacin; Cytoprotection; Diseas | 2016 |
Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Chemical and Drug Induced Live | 2015 |
Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Chemical and Drug Induced Live | 2015 |
Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Chemical and Drug Induced Live | 2015 |
Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Chemical and Drug Induced Live | 2015 |
A case report of highly suspected ciprofloxacin-induced hepatotoxicity.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Ciproflo | 2008 |
Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cefoxitin; Chemical and Drug Induced | 2009 |
Unexpected severe hepatotoxicity of ciprofloxacine: two case reports.
Topics: Alanine Transaminase; Anti-Infective Agents; Aspartate Aminotransferases; Chemical and Drug Induced | 2011 |
Re: Lasso-de-la-Vega et al. gabapentin as a probable cause of hepatotoxicity and eosinophilia.
Topics: Acetates; Amines; Analgesics; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Ciprofl | 2002 |
Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease.
Topics: Anti-Infective Agents; Bile Ducts; Chemical and Drug Induced Liver Injury; Cholestasis; Chronic Dise | 2002 |
Hepatitis associated with amoxicillin/clavulanic acid and/or ciprofloxacin.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Amoxicillin-Potassium Clavulana | 2003 |
Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ciprofl | 2004 |
Suspected ciprofloxacin-induced hepatotoxicity.
Topics: Administration, Oral; Adult; Chemical and Drug Induced Liver Injury; Ciprofloxacin; Endometritis; Fe | 1995 |
Cholestatic hepatitis related to quinolones: a report of two cases.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Cholestasis; | 1995 |
Ciprofloxacin safety in a pediatric population.
Topics: Adolescent; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 1997 |
Severe ciprofloxacin-induced acute hepatitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Ciprofloxacin; | 2001 |
Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database.
Topics: Adult; Aged; Anti-Infective Agents; Arrhythmias, Cardiac; Chemical and Drug Induced Liver Injury; Ci | 2001 |
Fulminant hepatic failure possibly related to ciprofloxacin.
Topics: Administration, Oral; Aged; Chemical and Drug Induced Liver Injury; Ciprofloxacin; Hip Prosthesis; H | 1992 |
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Amikacin; Chemical and Drug Induced Liver | 1990 |